Cargando…

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib

BACKGROUND: Sunitinib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors, and stem cell factor receptor (KIT). The ability of soluble (s)KIT, VEGF-A, sVEGFR-2, and sVEGFR-3 to predict clinical outcome was analyzed in 61 patients with previously t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keyvanjah, Kiana, DePrimo, Samuel E, Harmon, Charles S, Huang, Xin, Kern, Kenneth A, Carley, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499375/ https://www.ncbi.nlm.nih.gov/pubmed/22897944 http://dx.doi.org/10.1186/1479-5876-10-165

Ejemplares similares

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
por: Harmon, Charles S., et al.
Publicado: (2013)

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
por: Zurita, A J, et al.
Publicado: (2015)

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
por: DePrimo, Samuel E, et al.
Publicado: (2007)

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
por: Harmon, Charles S, et al.
Publicado: (2011)

Metastatic collecting duct carcinoma of the kidney treated with sunitinib
por: Tazi, El Mehdi, et al.
Publicado: (2011)

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
por: Reichardt, Peter, et al.
Publicado: (2016)

Retraction: metastatic collecting duct carcinoma of the kidney treated with Sunitinib
por: Tazi, El Mehdi, et al.
Publicado: (2011)

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
por: Mohammad, H., et al.
Publicado: (2021)

The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib
por: Frees, Sebastian, et al.
Publicado: (2018)

Soluble Isoforms of Vascular Endothelial Growth Factor Are Predictors of Response to Sunitinib in Metastatic Renal Cell Carcinomas
por: Paule, Bernard, et al.
Publicado: (2010)

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib
por: Billemont, B, et al.
Publicado: (2008)

A case of metastatic renal cell carcinoma treated effectively by gemcitabine and sunitinib
por: Morizane, Shuichi, et al.
Publicado: (2012)

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
por: Gu, Cheng-Yuan, et al.
Publicado: (2021)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
por: Fiala, Ondřej, et al.
Publicado: (2021)

Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
por: Witte, Jeannine, et al.
Publicado: (2018)

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
por: Rini, Brian I., et al.
Publicado: (2011)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
por: Beuselinck, B, et al.
Publicado: (2013)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
por: Keizman, Daniel, et al.
Publicado: (2016)

Acute Acalculous Cholecystitis in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib
por: da Fonseca, Leonardo Gomes, et al.
Publicado: (2014)

Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification
por: DePrimo, Samuel E, et al.
Publicado: (2003)

Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer
por: Ma, Xin, et al.
Publicado: (2016)

A Case of Metastatic Adamantinoma That Responded Well to Sunitinib
por: Liman, Andrew D., et al.
Publicado: (2016)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Metastatic Thymic Carcinoma with Long Survival After Treatment with Sunitinib
por: Cabezón-Gutiérrez, Luis, et al.
Publicado: (2018)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
por: Diekstra, Meta H. M., et al.
Publicado: (2022)

Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence
por: Wang, Denian, et al.
Publicado: (2020)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: van der Veldt, A A M, et al.
Publicado: (2010)

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
por: Powles, Thomas, et al.
Publicado: (2008)

A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine
por: Takayoshi, Kotoe, et al.
Publicado: (2015)

Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
por: Pilskog, Martin, et al.
Publicado: (2017)

Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: Lolli, Cristian, et al.
Publicado: (2016)

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
por: Barrios, Carlos H., et al.
Publicado: (2010)

Angiosarcoma of the Retroperitoneum: Report on a Patient Treated with Sunitinib
por: Yoo, Changhoon, et al.
Publicado: (2009)

Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
por: Jiménez-Fonseca, Paula, et al.
Publicado: (2018)

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients
por: Numakura, Kazuyuki, et al.
Publicado: (2018)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dev008223l4fleq26h9l3d762e